Description
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the first 29 residues of human growth hormone-releasing hormone (GHRH 1-29). It is studied as a selective agonist of the GHRH receptor on pituitary somatotrophs, where it stimulates pulsatile growth hormone (GH) release through cAMP-mediated signaling. Sermorelin retains the full biological activity of the native 44-amino-acid GHRH while offering improved synthetic accessibility, and has been investigated in preclinical and clinical research for over four decades as a tool for probing the somatotropic axis, IGF-1 dynamics, and age-related GH decline.
Product Highlights
• Each vial contains 10 mL solution (~100 sprays)
• Each spray delivers 0.1 mL = 50 mcg Sermorelin
• Total Sermorelin Content: 5 mg per vial
• Specialized pharmaceutical-grade nasal solution — designed for comfort and ease on the nose
• Unlike many other nasal sprays, this formula avoids irritation and dryness
• Packaged in Class A, lead-free pharmaceutical glass bottles
• Tamper/Child-Proof Cap + Orifice Reducer for integrity, sterility, and ease of use
Description
Sermorelin is explored for selective GHRH receptor activation and pulsatile growth hormone secretion, with research interest in somatotropic axis function, IGF-1 signaling, body composition, sleep architecture, and age-related endocrine changes.
Benefits
• GHRH receptor agonism — studied for selective activation of pituitary somatotroph GHRHR
• Pulsatile GH release — investigated for preserving physiological pulsatility unlike exogenous GH
• IGF-1 modulation — explored for downstream hepatic IGF-1 production and signaling
• Body composition research — examined for effects on lean mass, fat mass, and metabolic markers in aged models
• Sleep architecture — linked to slow-wave sleep enhancement in pituitary research
• Somatopause research — investigated as a probe for age-related decline in GH secretion
Localized Effects with Nasal Spray
• Rapid absorption through the nasal mucosa
• Bypasses first-pass hepatic metabolism that limits oral peptide bioavailability
• Convenient alternative delivery route for repeated-dose research protocols
• Sermorelin’s short native half-life (~10–20 min) aligns with frequent-dose research workflows
• Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness
What Researchers Use It For
• GHRH receptor pharmacology and pituitary somatotroph signaling studies
• GH pulsatility, IGF-1, and IGFBP-3 dynamics in endocrine research
• Age-related somatopause and GH-axis decline investigations
• Body composition and metabolic endpoints in aged rodent models
• Sleep architecture and slow-wave sleep research
• Comparative GHRH analog pharmacology (vs CJC-1295, Tesamorelin)
Identity & Specs
• Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (29 amino acids, C-terminal amide)
• Class: GHRH(1-29) analog; selective GHRH receptor agonist
• Formula / M.W.: C₁₄₉H₂₄₆N₄₄O₄₂S, ~3357.88 g/mol
• CAS: 86168-78-7
• Form: Sterile nasal spray solution
• Net per vial: 10 mL (~100 sprays)
• Total Content: 5 mg Sermorelin per vial
• Concentration: 0.5 mg/mL (50 mcg per 0.1 mL spray)
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: Refrigerate 2–8 °C, protect from light
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
